SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CuraGen (CRGN)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: CoffeePot who wrote (50)11/18/1998 8:10:00 PM
From: Terp  Read Replies (2) of 478
 
Pot, you better read this more carefully...

<<< it has discovered greater than 60,000 human genetic variations that may be responsible for the development of certain diseases. These single nucleotide polymorphisms (cSNPs) are variations in DNA that have accumulated over time in the general
population. Recently, cSNPs have become of increasing interest to
scientists because they are believed to be useful markers in the
identification of disease genes and genetic differences which may determine the response of a patient to disease and to drug treatment.
Richard Lifton, M.D., Ph.D., Howard Hughes Medical Institute Investigator and Professor at Yale University School of Medicine, said, "SNPs are the most frequent type of genetic variation found in the human genome. Although most SNPs are found outside expressed genes, cSNPs are found in coding regions of genes and may provide important predictions about responses to drugs and disease predisposition.(1) Currently, there are approximately 5,000 publicly known SNPs and these were derived from random genomic DNA. Therefore, by identifying vast numbers of cSNPs, CuraGen is well-positioned for discovering key variations associated with specific human diseases and
drug responses.">>>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext